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266 The Journal of Thoracic and CardioIn this issue of the Journal, Carrier and colleagues1 report on a subgroup analysisof the PRIMO-CABG study,* in which patients undergoing combined coronaryartery bypass grafting (CABG) and aortic valve replacement receive either
placebo or the complement C5-binding monoclonal antibody pexelizumab. The
initial phase II prospective multicenter trial on the use of pexelizumab during
coronary and valve surgery in 914 patients2 found no significant effect on mortality.
Post hoc analysis, however, suggested that for isolated CABG, pexelizumab did
reduce death or myocardial infarction. Some of the same investigators published the
benefit of pexelizumab on cognitive decline and stroke after CABG. The authors
reported no differences, except for a slight improvement in the visuo-spatial do-
main.3 The PRIMO-CABG study was a multi-institutional, randomized trial eval-
uating a complement C5-binding monoclonal antibody in 3099 cardiac surgery
patients with regard to combined mortality or myocardial infarction. The primary
end point within 30 days after surgery was reduced by about 20% in patients with
isolated CABG treated with pexelizumab compared with control patients.4 In the
current article, the authors continue their series of studies of patients who are part
of the same trial of the complement-binding protein in cardiac surgery in which
cardiopulmonary bypass is used. The current study clearly demonstrates a benefit of
pexelizumab in reducing both 30-day (3.8% vs 9.9%) and 180-day (5.7% vs 14.4%)
mortality in this select, and presumably high-risk, group of patients.
Complement evolved to fight bacterial and other types of infection in a hostile
environment. When man was swinging through trees and being chased by tigers,
infection and bleeding were the major causes of death. In the modern era, bleeding
usually occurs during surgery or after being shot or stabbed, and infection occurs
less often. It does often occur in patients who undergo surgery and especially
cardiac surgery. During cardiopulmonary bypass, complement is activated owing to
antigen-antibody interaction or ischemia-reperfusion (classical pathway) and by
contact of blood with foreign substances (alternative pathway). In addition, com-
plement can be activated after contact of blood with microbial surfaces in the
recently discovered lectin pathway. Although an exhaustive description of the
complement system is not here described, two of the main players in complement
activation are C5, which cleaves to the very chemotactic fragment C5a, and C5b,
which leads to formation of the terminal membrane attack complex C5b-9. C5b-9 is
proteolytic and causes direct tissue injury.
The prevention of this cleavage of C5 by binding C5 with a monoclonal antibody
is the theoretical basis for why pexelizumab should work. Instead of being life
saving, complement activation during cardiopulmonary bypass may actually de-
crease the likelihood of an uneventful recovery and lead to myocardial infarction,
lung injury, or stroke.
Prospective, randomized, double-blind, placebo-controlled, multicenter trials are
difficult, labor intensive, and expensive to carry out. Such clinical investigations as
the one described in this article should be encouraged. Industry sponsors desire valid
documentation of efficacy and academic investigators desire and deserve credit for
their work. In part because of a desire to report positive results, there is a temptation
in large, multicenter trials to go back and “post hoc” analyze multiple different
groups. The authors are very qualified clinical investigators, and they understand
that the primary and secondary end points must be identified before the study is*Pexelizumab for Reduction in Infarction and Mortality in Coronary Artery Bypass Graft surgery.
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Linitiated. The primary end point in the PRIMO-CABG trial
was “composite of death, myocardial infarction, or both at
postoperative day 30 in patients undergoing coronary artery
bypass grafting without valve surgery.” The authors make
the point that valve-CABG patients were not included in the
primary population and therefore separate analysis of death
and myocardial infarction of the 218 patients undergoing com-
bined aortic valve replacement and CABG is permissible.
Another issue that arises from this study relates to the
optimal selection of end points. The ideal end point is
clinically relevant, objectively ascertained, and occurs at a
sufficient frequency in the study population so as to allow
the design of an adequately powered clinical trial without
breaking the budget. Unfortunately, such end points rarely
exist. The result is composite end points that often combine
clinically significant or hard end points, which occur at a
low frequency with less clinically important end points (soft
end points), which are more common. Increasingly, surro-
gate end points consisting of biomarkers, functional assess-
ments, or quality of life measurements are taking the place
of or being combined with traditional hard clinical end
points. In this study, the pre-specified composite end point
consisted of all-cause mortality and myocardial infarction.
Although a difference in mortality is unarguably of clinical
importance, a difference in perioperative creatine kinase
MB elevation is less so. In such situations in which the
components of the composite end point carry unequal
“weight,” the differences in composite end points become
more difficult to interpret. The optimal composite end point,
therefore, would be one in which the components carry
roughly equal clinical “weight,” that is, are of equal clinical
significance.
Furthermore, the end points need to be tailored to the
patient population as well as the disease mechanism being
studied. For example, when a drug that prevents ischemia-
reperfusion and inflammatory myocardial injury is being
evaluated, myocardial infarction is a “cleaner” end point in
patients undergoing isolated valve surgery; that is, it is not
confounded by other determinants of myocardial infarction
like extent and diffuseness of coronary disease, types of
grafts used, or history of myocardial infarction. In a group
of patients undergoing CABG in addition to valve surgery,
these and other confounders that can affect the rates of
perioperative myocardial injury may not be equally distrib-
uted among the treatment and control groups, particularly
The Journal of Thoraciwhen the sample size is relatively small. In the present
study, there are statistically nonsignificant but potentially
important differences in New York Heart Association class
status, prior myocardial infarction, and number of grafts per
patient. In addition, certain other patient- and disease-
related variables that are not reported or measured may
differ between groups. This, again, reinforces the need to
pre-specify the subgroups and end points that are to be
analyzed at the design stage, ensuring that a large enough
sample size exists to allow the results of these subgroup
analyses to be meaningful and generalizable.
Finally, the question must be raised as to whether such a
drug is necessary to improve the outcome of patients after
complex cardiac operations during which time the patient is
subjected to cardiopulmonary bypass. For most low-risk
cardiac procedures, patients will not likely benefit. How-
ever, for very ill patients undergoing prolonged, compli-
cated operations, selective inhibition of complement may
improve the outcome, as demonstrated in the present study.
In these days when hospital administrators keep track of
costs of doing cardiac surgery, the cost of pexelizumab will
no doubt affect how often it is administered. Clearly not
everyone will receive it at even a modest incremental cost,
but at very high cost, very few will receive the drug. The
efficacy, as determined by the results of the recently com-
pleted PRIMO-CABG II trial, in which additional patients
were enrolled, and the cost of the drug, will determine the
place of pexelizumab in the treatment of patients having
cardiac surgery and in the market.
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